Madison Asset Management’s Castle Biosciences CSTL Stock Holding History

Madison Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-60,783	Closed	-$2.73M	–	365
2022 Q1	$2.73M	Sell	60,783 -128	-0.2%	-$5.29K	0.04%	226
2021 Q4	$2.61M	Buy	60,911 +453	+0.7%	+$23.7K	0.03%	239
2021 Q3	$4.02M	Sell	60,458 -10,979	-15%	-$773K	0.06%	210
2021 Q2	$5.24M	Buy	71,437 +14,456	+25%	+$955K	0.07%	183
2021 Q1	$3.9M	Buy	56,981 +36,981	+185%	+$2.78M	0.05%	213
2020 Q4	$1.34M	Buy	+20,000	New	+$1.08M	0.02%	250

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Madison Asset Management's CSTL Position: Q2 2022 in Review

Madison Asset Management sold out of Castle Biosciences (CSTL) in Q2 2022, closing a stake of 60,783 shares — an estimated $2.73M sold.

Madison Asset Management first reported a position in CSTL in Q4 2020 and held it in 6 quarters. The position peaked at $5.24M in Q2 2021. 146 funds tracked by Wall St. Rank hold CSTL as of Q2 2022.

Madison Asset Management reported no remaining Castle Biosciences position as of Q2 2022 after selling out during the quarter.
Madison Asset Management sold 60,783 Castle Biosciences shares in Q2 2022, an estimated $2.73M.
Madison Asset Management first reported a position in Castle Biosciences in Q4 2020 and held it in 6 quarters.
Madison Asset Management's Castle Biosciences position peaked at $5.24M in Q2 2021.
146 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2022.

Based on Madison Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.